Shares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) rose 7.8% on Tuesday . The stock traded as high as $13.67 and last traded at $13.59. Approximately 373,840 shares changed hands during mid-day trading, a decline of 35% from the average daily volume of 573,232 shares. The stock had previously closed at $12.61.
Analyst Ratings Changes
Several equities analysts recently commented on PRTA shares. Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research report on Monday, September 30th. Bank of America cut their price objective on Prothena from $33.00 to $31.00 and set a "neutral" rating for the company in a report on Tuesday, October 1st. HC Wainwright restated a "buy" rating and issued a $84.00 target price on shares of Prothena in a research note on Wednesday, November 13th. Finally, StockNews.com cut shares of Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Prothena currently has a consensus rating of "Hold" and an average price target of $61.83.
Get Our Latest Stock Report on PRTA
Prothena Stock Up 11.3 %
The stock has a fifty day moving average of $15.89 and a 200-day moving average of $19.26. The firm has a market capitalization of $755.48 million, a P/E ratio of -5.66 and a beta of 0.09.
Prothena (NASDAQ:PRTA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.18) by $0.08. The company had revenue of $0.97 million during the quarter, compared to the consensus estimate of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company's revenue was down 98.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 earnings per share. As a group, analysts forecast that Prothena Co. plc will post -2.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of PRTA. Signaturefd LLC lifted its stake in shares of Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 863 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Prothena by 13.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock valued at $211,000 after purchasing an additional 1,186 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Prothena by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,344 shares of the biotechnology company's stock valued at $173,000 after purchasing an additional 4,026 shares during the period. Intech Investment Management LLC bought a new position in shares of Prothena in the 3rd quarter valued at about $210,000. Finally, XTX Topco Ltd acquired a new stake in shares of Prothena during the 3rd quarter worth approximately $260,000. 97.08% of the stock is currently owned by institutional investors.
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
